StocksMedium•6 November 2026•
1 min read
iRhythm Raises 2026 Revenue Outlook and Sets 2027 FDA Filing Timeline
Key Facts
1iRhythm raised its full-year 2026 revenue guidance to a range of $890 million to $895 million.
2The company plans to submit an FDA filing for its Zio MCT device in 2027.
iRhythm raised its full-year 2026 revenue guidance to a range of $890 million to $895 million. Seeking Alpha reported that the updated outlook follows the company's third-quarter performance and strategic planning for its product pipeline.
The company plans to submit an FDA filing for its Zio MCT device in 2027. This regulatory timeline reflects long-term product development goals amid continued growth in the medical devices sector, though no specific price levels were recorded for iRhythm shares on November 6, 2026.